CEACAM5 and cancer: Moreover, targeting of CEACAMs holds promising role in the treatment of patients with NSCLC among other cancers [33,34] and a randomized, phase 3 study is already investigating the efficacy of antibody-based targeting of CEACAM5 (SAR408701) to improve PFS and OS in patients with previously treated metastatic NSCLC (NCT04154956).